Intervention to Preserve Beta-Cell Function in GAD Ab-Positive Diabetes

• Status: Completed
• Trial end date: 2005-01-01
• Target enrollment: 0
• Participant gender: All

Summary

We tested the hypothesis that insulin therapy rather than sulfonylurea (SU) treatment has a preferable outcome to reverse or preserve beta cell function in the patients with diabetes that is called slowly progressive insulin-dependent (type 1) diabetes (SPIDDM) or latent autoimmune diabetes in adult (LADA).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tokyo Study Group
• Treatments: Insulin

Criteria

Inclusion Criteria:

• Subjects should use SU agents to obtain as a goal good glycemic control.

• Duration of diabetes within 5 years from the onset (or diagnosis).

Exclusion Criteria:

• Subjects having history of hyperglycemia requiring insulin treatment and/or history of ketosis/ketoacidosis were excluded.

• Subjects with malignant diseases, systemic inflammatory diseases, renal or liver disorders or malabsorption were also excluded.